SWK Holdings
SWK Holdings specializes in providing capital solutions for commercial-stage healthcare and life science companies, focusing on sub-$50 million opportunities. Headquartered in Dallas, Texas, the company has funded nearly $620 million through 43 transactions and operates Enteris Biopharma, which enhances drug solubility with Peptelligence technology.
Services
SWK Holdings specializes in providing capital solutions to commercial-stage healthcare and life science companies, as well as royalty owners. Their bespoke capital solutions are designed to preserve ownership interests while offering a variety of financing structures. These structures focus on maximizing operational flexibility and increasing the equity value of their partners.
Sector
SWK Holdings operates primarily in the healthcare and life science sectors, targeting sub-$50 million opportunities. Their focus is on providing financial assistance and solutions to companies within these industries, helping to drive growth and innovation.
History
Since its inception, SWK Holdings has successfully closed 43 transactions, injecting nearly $620 million into the life science industry. This demonstrates their significant impact and presence within the sector. The company is headquartered in Dallas, Texas, establishing a strong base for their operations and outreach.
Enteris Biopharma
SWK Holdings operates Enteris Biopharma, a subsidiary that collaborates with pharmaceutical partners. Enteris Biopharma focuses on enhancing the solubility and delivery of hard-to-dose therapeutics through its proprietary Peptelligence drug delivery technology. This innovative approach supports the development and effectiveness of pharmaceutical products.